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The bacterial pathogens of the genus 
 
Yersinia
 
, the causative agents of plague, septicemia, 
and gastrointestinal syndromes, use a type III secretion system to inject virulence factors 
into host target cells. One virulence factor, YopJ, is essential for the death of infected 
macrophages and can block host proinflammatory responses by inhibiting both the nuclear 
factor 
 
 
 
B (NF-
 
 
 
B) and mitogen-activated protein kinase pathways, which might be important 
for evasion of the host immune response and aid in establishing a systemic infection. Here, we 
show that YopJ is a promiscuous deubiquitinating enzyme that negatively regulates signaling by 
removing ubiquitin moieties from critical proteins, such as TRAF2, TRAF6, and I
 
 
 
B
 
 
 
. In 
contrast to the cylindromatosis tumor suppressor CYLD, which attenuates NF-
 
 
 
B signaling 
by selectively removing K63-linked polyubiquitin chains that activate I
 
 
 
B kinase, YopJ also 
cleaves K48-linked chains and thereby inhibits proteasomal degradation of I
 
 
 
B
 
 
 
. YopJ, but 
not a catalytically inactive YopJ mutant, promoted deubiquitination of cellular proteins and 
cleaved both K48- and K63-linked polyubiquitin. Moreover, an in vitro assay was 
established to demonstrate directly the deubiquitinating activity of purified YopJ.
 
Pathogenic Yersinia, 
 
Yersinia pseudotuberculosis
 
,
and 
 
Yersinia enterocolitica
 
 must express the cysteine
protease YopJ to kill infected macrophages and
establish a systemic infection in mice (1–4).
Other members of the family of cysteine pro-
teases to which YopJ belongs include the ade-
novirus protease AVP, the proapoptotic protein
AvrA of 
 
Salmonella typhimurium,
 
 and the 
 
Xan-
thomonas campestris
 
 
 
pv.
 
 
 
vesicatoria
 
 protein AvrBsT,
which induces localized cell death in infected
plant leaves (4). Mutation of the conserved
catalytic cysteine in YopJ abolishes its ability to
inhibit the proinflammatory mitogen-activated
protein kinase (MAPK) and NF-
 
 
 
B pathways
that are activated within infected cells, and it
has been suggested that YopJ proteolytic activity
is required to remove the ubiquitin-like protein
SUMO-1 from posttranslationally modified
proteins (4). However, the proteins that must
be de-sumoylated to shut down NF-
 
 
 
B or
MAPK signaling remain ill defined. In this
study, we identify YopJ as a promiscuous de-
ubiquitinating protease that negatively regulates
the host cell response by cleaving ubiquitin
moieties from critical proteins, such as TRAF2,
TRAF6, and I
 
 
 
B
 
 
 
.
 
RESULTS AND DISCUSSION
 
To identify the YopJ substrates that are critical
to NF-
 
 
 
B signaling, we began by comparing
the impact of YopJ on NF-
 
 
 
B activation in
response to a variety of different stimuli.
HEK293T cells were cotransfected with YopJ,
a NF-
 
 
 
B–dependent reporter gene, and one of
the following activators of NF-
 
 
 
B transcrip-
tion: TRAF6, which is essential for NF-
 
 
 
B
signaling when LPS engages Toll-like receptor
4; TRAF2 or TRAF5, which signal NF-
 
 
 
B
activation downstream of TNF receptor 1; NIK,
which signals NF-
 
 
 
B activation downstream
of the lymphotoxin 
 
 
 
 receptor and the BAFF/
BLyS receptor 3; IKK
 
 
 
 or IKK
 
 
 
, components
of the I
 
 
 
B kinase (IKK) complex that is acti-
vated by diverse stimuli to phosphorylate I
 
 
 
B
proteins and thereby targets them for ubiquitin-
mediated degradation; and c-Rel, a member of
the NF-
 
 
 
B family of transcription factors (Fig.
1 A and see Fig. 3 B; references 5–7). NF-
 
 
 
B
transcriptional activity in response to overex-
pression of TRAF6, TRAF2, NIK, IKK
 
 
 
, or
IKK
 
 
 
 was markedly reduced by WT YopJ,
but not by the catalytic cysteine YopJ mutant
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C172A. These results indicate that YopJ can inhibit NF-
 
 
 
B
signaling in response to diverse stimuli and that inhibition is
dependent on its protease activity. WT YopJ did not, how-
ever, block NF-
 
 
 
B activation after c-Rel overexpression,
indicating that YopJ does not have a direct effect on the
transcriptional activity of NF-
 
 
 
B (Fig. 1 A).
Given that SUMO-1–conjugated proteins have been re-
ported as targets for YopJ (4), we next examined whether
sumoylation of signaling components is a requirement for
NF-
 
 
 
B activation, such that removal of SUMO-1 by YopJ
might lead to inhibition of the NF-
 
 
 
B pathway. To test this
hypothesis, we transfected 293T cells with siRNA against
Ubc9, the E2 enzyme essential for protein sumoylation (8–9),
and determined whether TRAF2, TRAF6, or IKK
 
 
 
 still acti-
vated an NF-
 
 
 
B–dependent reporter gene (Fig. 1 B). Signifi-
cant knockdown of Ubc9 expression was confirmed by West-
ern blotting (Fig. 1 C), but there was no inhibition of
TRAF2-, TRAF6-, or IKK
 
 
 
-induced NF-
 
 
 
B activity (Fig. 1
B). We verified that Ubc9 knockdown inhibited sumoylation
by Western blotting of RanGAP1, a known target for sumo-
ylation (10–11). The slower migrating form of RanGAP1 con-
jugated to SUMO-1 was abolished in cells transfected with
Ubc9 siRNA (Fig. 1 D). These data suggest that sumoylation
may not be required for NF-
 
 
 
B activation, at least in response
to expression of TRAF2, TRAF6, or IKK
 
 
 
, which brings
into question the notion that YopJ inhibits NF-
 
 
 
B signaling
by functioning as a SUMO-1 isopeptidase.
Recent studies have identified a critical role for ubiquiti-
nation in NF-
 
 
 
B signaling. For example, TRAF2 and
TRAF6 undergo autoubiquitination and acquire polyubiq-
uitin chains in which lysine 63 (K63) of one ubiquitin is
linked to the COOH terminus of an adjacent ubiquitin.
Modification of TRAF2 or TRAF6 in this manner is pro-
posed to promote the assembly of a multiprotein complex
that activates the IKK complex and hence, NF-
 
 
 
B signaling
(12–14). The cylindromatosis tumor suppressor protein
CYLD recently was defined as a deubiquitinating protease
that inhibits TRAF2- and TRAF6-induced NF-
 
 
 
B activa-
tion by cleaving K63-linked ubiquitin chains (15–17). There-
fore, we explored whether YopJ might also inhibit the NF-
 
 
 
B pathway by targeting ubiquitinated proteins rather than
proteins conjugated to SUMO-1. To facilitate the detection
of ubiquitin and SUMO-1 conjugates, 293T cells expressing
YopJ were also transfected with SUMO-1 or ubiquitin hav-
ing NH
 
2
 
-terminal hemagglutinin (HA) epitope tags. Immu-
noblotting of whole cell lysates with HA antibodies revealed
that cells expressing YopJ contained far fewer ubiquitinated
proteins than cells not expressing YopJ (Fig. 2 A, left). By
contrast, YopJ did not decrease total cellular sumoylated pro-
tein levels (Fig. 2 A, right). The decrease in cellular ubiquiti-
nated proteins mediated by YopJ was dependent on YopJ
protease activity because the catalytic cysteine YopJ mutant
C172A did not reduce ubiquitinated protein levels (Fig. 2 A).
Consistent with the work of others (10–12), basal levels of
total cellular ubiquitinated proteins in 293T cells, but not
sumoylated proteins, were elevated further by overexpression
of TRAF2 or TRAF6 (Fig. 2 B and not depicted). WT
YopJ, but not YopJ mutant C172A, prevented this increased
level of ubiquitinated proteins, further supporting the possi-
bility that YopJ inhibits NF-
 
 
 
B signaling by acting as a de-
ubiquitinating protease rather than a SUMO-1 isopeptidase.
To test whether ubiquitinated TRAF2 and TRAF6 are
substrates for YopJ, TRAF2 or TRAF6 was overexpressed
with HA ubiquitin and YopJ and then immunoprecipitated
from denatured cell lysates and immunoblotted with HA an-
tibody. YopJ, but not YopJ mutant C172A, abolished
TRAF2 and TRAF6 autoubiquitination (Fig. 2 C). This in-
hibition of TRAF2 and TRAF6 autoubiquitination by YopJ
correlated not only with inhibition of NF-
 
 
 
B signaling (Fig.
1 A), but also with impaired activation of extracellular-regu-
lated kinases (ERKs) 1 and 2, Jun NH
 
2
 
-terminal kinases 1
Figure 1. YopJ inhibits NF- B activation by diverse stimuli. (A) HEK 
293T cells were transfected with an NF- B–dependent reporter gene, the 
indicated activator of NF- B signaling, and either control empty vector (v), 
WT YopJ (wt), or YopJ mutant C172A (mt). NF- B activation was measured 
by dual-luciferase reporter assay after 36 h and is presented as a percentage 
of the activity induced by TRAF2 (lane 1), TRAF6 (lane 4), or Rel (lane 7) 
alone. Expression of YopJ, TRAF2, TRAF6, and Rel was confirmed by Western 
blotting (not depicted). (B) 293T cells that were transfected with siRNAs 
targeting Ubc9 or a nonspecific siRNA (ns) were cotransfected with Flag-
tagged TRAF2, TRAF6, or IKK , and NF- B activation was measured after 
36 h. NF- B activity is presented as a percentage of the activity induced 
by either TRAF2, TRAF6, or IKK  in the absence of any siRNA oligos. (C) Cell 
lysates from B were Western blotted for Ubc9 (top), Ubc13 (middle), and 
TRAF2, TRAF6, or IKK  (bottom). (D) 293T cells that were transfected with 
or without siRNAs targeting Ubc9 were cotransfected with RanGAP1. 
Modification of RanGAP1 by SUMO-1 was measured after 36 h by immu-
noblotting with RanGAP1 antibody (top). The actin blot shows equal 
protein loading (bottom). 
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and 2, and p38 MAPK (Fig. 2 D; references 18–20). These
results suggested that YopJ, like CYLD, prevents NF-
 
 
 
B
signaling by acting as a deubiquitinating protease. However,
when we compared the activities of YopJ and CYLD in our
assay systems (Fig. 3), differences between the two were ap-
parent. Although YopJ inhibited expression of an NF-
 
 
 
B–
dependent reporter in response to overexpression of
TRAF2, TRAF6, IKK
 
 
 
, IKK
 
 
 
, and NIK, CYLD was only
effective at blocking NF-
 
 
 
B signaling by TRAF2 and
TRAF6 (Fig. 3, A and B). We also tested whether the lysine
residue in ubiquitin that is used to assemble polyubiquitin
chains impacts deubiquitination by YopJ and CYLD. For
example, while TRAF2 and TRAF6 undergo “activating”
K63-linked autoubiquitination, K48-linked polyubiquitin
chains play an important role in NF-
 
 
 
B signaling by target-
ing phosphorylated I
 
 
 
B proteins for degradation in the 26S
proteasome (21–23). To assess whether YopJ can promote
the cleavage of K48-linked polyubiquitin chains as well as
K63-linked chains, which are attached to TRAF2 and
TRAF6, we expressed TRAF6 in cells to activate NF-
 
 
 
B
signaling and used the proteasome inhibitor MG132 to trap
the predominantly K48-linked polyubiquitinated proteins
that would otherwise be degraded and not detected. We
found that WT YopJ, but not CYLD, was able to block the
accumulation of ubiquitinated proteins that occurred in cells
treated with MG132 (Fig. 3 C). Next, we focused directly
on K48- and K63-linked polyubiquitin chains by cotrans-
fecting cells with TRAF6 and HA-tagged ubiquitin that had
every lysine residue except K48 or K63 mutated to arginine
(Fig. 3 D). MG132 treatment was used again to prevent the
degradation of cellular proteins modified by K48-linked
polyubiquitin chains. Western blotting with anti-HA anti-
bodies revealed that YopJ interfered with the accumulation
Figure 2. YopJ decreases cellular proteins modified by polyubiquitin 
chains but not proteins conjugated to SUMO-1. (A) 293T cells were 
transfected with HA-SUMO or HA-ubiquitin together with control empty 
vector (v), Flag-tagged WT YopJ (wt), or Flag-tagged YopJ mutant C172A 
(mt). Total sumoylated and ubiquitinated cellular proteins were detected 
by Western blotting with HA antibodies. (B) Western blot analysis of 293T 
cells transfected with Flag-tagged WT YopJ (wt) or YopJ mutant C172A 
(mt), HA-ubiquitin, and Flag-tagged TRAF2 or TRAF6. (C) TRAF2 or TRAF6 
autoubiquitination was analyzed by immunoprecipitation of the proteins 
from denatured 293T cell lysates followed by immunoblotting with HA 
antibody (top) or anti-FLAG antibody (bottom). (D) Lysates from 293T cells 
transfected with the constructs indicated were Western blotted with 
phospho-specific antibodies recognizing activated ERK1/2, p38 MAPK, or 
Jun NH2-terminal kinases 1/2 (left). Western blots for all forms of ERK1/2 
and p38 MAPK are also shown.
Figure 3. Comparison of YopJ and CYLD activities. (A and B) 293T 
cells were transfected with an NF- B–dependent reporter gene, the indi-
cated activator of NF- B signaling, and either control empty vector (v), WT 
YopJ (wt), YopJ mutant C172A (mt), or CYLD. NF- B activation was measured 
by dual-luciferase reporter assay after 36 h. (C) 293T cells were transfected 
with HA-ubiquitin and either empty vector (v), Flag-tagged WT YopJ (wt), 
Flag-tagged YopJ mutant C172A (mt), or Flag-tagged CYLD. Cells were then 
treated with 50  M MG132 for 1 h before harvesting. Total cellular 
ubiquitinated proteins were detected by Western blotting with HA antibod-
ies. (D) 293T cells were transfected with HA-tagged “K48-only” ubiquitin or 
“K63-only” ubiquitin together with TRAF6, WT YopJ, or CYLD. Cells were 
treated with 50  M MG132 for 1 h before harvesting and analyzed as in C. 
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of proteins with K48- or K63-linked polyubiquitin chains,
whereas CYLD only blocked the accumulation of proteins
with K63-linked polyubiquitin chains (Fig. 3 D). These data
indicate that YopJ can promote the cleavage of both K48-
and K63-linked polyubiquitin chains and, as such, has much
broader target specificity than CYLD. This difference might
account for the ability of YopJ to inhibit NF-
 
 
 
B signaling in
more settings than CYLD. For example, YopJ can inhibit
NIK-induced NF-
 
 
 
B activation but CYLD cannot (Fig. 3
B). Such promiscuity in a bacterial enzyme would enable ef-
ficient shutdown of the multiple signaling pathways that
contribute to the host immune response. Similar substrate
promiscuity is associated with another Yersinia virulence
factor, the tyrosine phosphatase YopH (24–25).
YopJ is essential for 
 
Y. pseudotuberculosis
 
–induced macro-
phage apoptosis and is important for establishing a systemic
infection in mice as indicated by increased clearance of a 
 
yopJ
 
mutant 4 d after an oral infection in mice (2, 3, 26). Thus, to
extend our findings in 293T cells, we tested the importance
of the deubiquitinating activity associated with YopJ in the
relevant setting of an actual bacterial infection. Mouse mac-
rophages were infected with either WT 
 
Y. pseudotuberculosis
 
or a YopJ-null strain of 
 
Y. pseudotuberculosis
 
 that had been
complemented with the catalytic cysteine YopJ mutant
C172A. Western blot analysis of whole cell lysates was per-
formed at different times after infection (Fig. 4 A). At 5 min
after infection, phosphorylated I
 
 
 
B
 
 
 
 was observed in mac-
rophages infected with WT YopJ 
 
Y. pseudotuberculosis
 
 as well
as in macrophages infected with YopJ C172A 
 
Y. pseudotuber-
culosis
 
, suggesting that both bacteria initially induced similar
activation of the IKK complex, presumably through engage-
ment of surface Toll-like receptors (Fig. 4 A, top; compare
lanes 1, 2, and 6). Interestingly, the levels of phosphorylated
I
 
 
 
B
 
  remained elevated even at 60 min after infection with
WT YopJ Y. pseudotuberculosis, whereas levels of phosphory-
lated I B  in cells infected with YopJ C172A Y. pseudotuber-
culosis were greatly decreased by 30 min after infection (Fig.
4 A, top; compare lanes 4 and 8). Immunoblotting for total
I B  levels confirmed that I B  was degraded in cells in-
fected with YopJ C172A Y. pseudotuberculosis but not in cells
infected with WT YopJ (Fig. 4 A, middle; compare lanes 4
and 8). Phosphorylation of I B  normally is a prerequisite
for its ubiquitination and degradation by the proteasome (5),
so we investigated whether phosphorylated I B  was not
degraded in cells infected with WT YopJ Y. pseudotuberculosis
because it was deubiquitinated efficiently by YopJ. To test
this hypothesis, we treated macrophages with the protea-
some inhibitor MG132 before infection to trap and detect
the otherwise highly labile ubiquitinated I B . At different
times after infection, I B  was immunoprecipitated from
boiled lysates and immunoblotted with ubiquitin antibodies
(Fig. 4 B). High molecular weight bands, consistent with
polyubiquitinated I B , were observed by 5 min after infec-
tion in cells infected with WT YopJ or YopJ mutant C172A
bacteria. Notably, these higher molecular weight species
then disappeared rapidly from cells infected with WT YopJ
Y. pseudotuberculosis despite the presence of MG132 (Fig. 4
B). By contrast, the polyubiquitinated I B  was still evident
in cells infected with YopJ C172A Y. pseudotuberculosis at 60
min after infection. These results indicate that YopJ plays an
essential role in reversing the ubiquitination of phosphory-
lated I B  during Yersinia infection. Consequently, NF- B
transcription factors would stay sequestered in the cytoplasm
by intact I B , thereby attenuating the antiapoptotic NF-
 B pathway (2, 26, 27). We propose that the reason the IKK
complex can still be activated in macrophages infected with
WT YopJ Y. pseudotuberculosis (Fig. 1 A), despite the fact that
YopJ can promote the deubiquitination of such upstream
components as TRAF2 and TRAF6 (Fig. 2 C), is that at-
tachment of Yersinia to the macrophage surface activates NF-
 B signaling through Toll-like receptors (28) and perhaps
additional cell surface receptors before the time that YopJ is
Figure 4. YopJ decreases cellular proteins modified by polyubiquitin 
chains during Yersinia infection of macrophages. (A) Mouse macrophages 
were untreated or infected with Y. pseudotuberculosis expressing WT YopJ 
or YopJ mutant C172A and subjected to Western blot analysis with antibodies 
to phosphorylated I B  (top), total I B  (middle), or actin (bottom). 
(B) Mouse macrophages were treated with 50  M MG132 for 1 h and 
then infected with Y. pseudotuberculosis expressing either WT YopJ or 
YopJ mutant C172A. I B  was immunoprecipitated from boiled lysates at 
the times indicated and immunoblotted with antibodies against ubiquitin.JEM VOL. 202, November 21, 2005 1331
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injected into the macrophage by the bacteria’s type III secre-
tion system. Consistent with this notion, by immuno-gold
labeling and electron microscopy, substantial levels of YopJ
could not be detected in macrophages infected with Y.
pseudotuberculosis until 15 min after infection (not depicted), a
time when I B  is already phosphorylated (Fig. 4 A).
These results indicate that YopJ promotes deubiquitina-
tion, though it remains uncertain whether YopJ has intrinsic
deubiquitinating activity or regulates ubiquitination indirectly
via other proteins in cells. To demonstrate deubiquitinating
activity for YopJ directly, we purified WT YopJ and YopJ
mutant C172A from insect cells (Fig. 5 A) and incubated
them with ubiquitin-7-amino-4-methylcoumarin (ubiquitin-
AMC) in an in vitro deubiquitination assay (Fig. 5 B). Puri-
fied WT YopJ cleaved ubiquitin-AMC, but not SUMO-1–
AMC, as judged by the release of fluorescent AMC, whereas
YopJ mutant C172A was inactive against ubiquitin-AMC.
Cleavage of SUMO-1–AMC under these experimental con-
ditions was observed with recombinant SUMO protease 1
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20051194/DC1). These results indicate that YopJ pos-
sesses intrinsic deubiquitinating protease activity that requires
cysteine 172. YopJ cleaved ubiquitin-AMC with a Km of
 3.0 uM, which is comparable with that of other known
deubiquitinating proteases (29).
In sum, we provide the first direct evidence that a bacte-
rial virulence factor, YopJ, is a deubiquitinating protease and
have shown that this activity is responsible for YopJ-medi-
ated inhibition of NF- B and MAPK signaling. Given that
YopJ and its related proteins function as virulence factors in
bacteria that cause: (a) plague or black death (Yersinia pestis),
a disease of historical significance and of recent interest due
to the threat of bioterrorism, (b) gastroenteritis (Y. pseudotu-
berculosis, Salmonella typhimurium), and (c) black rot in plants
(Xanthomonas campestris), the finding that purified YopJ is a
deubiquitinase provides a facile enzymatic assay for the even-
tual development of a therapeutic inhibitor. Additionally, it
is likely that interfering with ubiquitin signaling in the host
might be a common strategy used by pathogens to evade the
host immune system during the course of infection.
MATERIALS AND METHODS
Transfection experiments. 293T cells were transfected with Lipo-
fectamine 2000 (Invitrogen). Luciferase assays were performed as described
previously (30). Ubc9 siRNA duplexes with 3  dTdT overhangs (Genen-
tech, Inc.) or scramble II siRNA duplexes (Dharmacon) were transfected
twice at 24-h intervals, with the cells being split to 80% confluency before
the second transfection. Expression constructs were also included in the sec-
ond transfection, and lysates were collected after an additional 36 h. Cells
washed with PBS were lysed for 0.5 h at 4 C in 120 mM NaCl, 50 mM
Hepes, pH 7.2, 1 mM EDTA, 0.1% NP-40, and complete protease inhibi-
tor cocktail (Roche). Proteins were immunoprecipitated for 2–16 h at 4 C
and then washed three times in lysis buffer. To assess ubiquitination, lysates
were supplemented with 1% SDS (vol/vol) and heated at 90 C for 5 min.
Samples were then diluted 10-fold with lysis buffer, and immunoprecipita-
tions were performed.
Purification of YopJ. Recombinant baculoviruses to express WT YopJ
or YopJ mutant C172A with NH2-terminal 6xHIS tags from the polyhedrin
promoter were generated in sf9 cells cotransfected with baculovirus gold
DNA and YopJ sequences cloned into pVL1932 (BD Biosciences). Hi5 cells
were infected with virus at a multiplicity of infection of 5:1 at 27 C for 3 d.
Infected cells were lysed during three freeze/thaw cycles in 50 mM Tris, pH
8.0, 500 mM NaCl, 0.1% Triton X-100, and 2 mM  -mercaptoethanol.
Soluble HIS-tagged proteins were recovered from a Ni-NTA agarose col-
umn (QIAGEN) in 50 mM Tris, pH 8.5, 300 mM NaCl, 2 mM  -mercap-
toethanol, and 250 mM imidazole. Monomeric YopJ was obtained using a
Superdex-75 gel filtration column (GE Healthcare) equilibrated with 50 mM
Tris, pH 8.5, 250 mM NaCl, and 5 mM  -mercaptoethanol.
Protease assays. WT YopJ, mutant YopJ, or SUMO protease 1 ( 140
nM; LifeSensor Inc.) was incubated with ubiquitin-AMC or Sumo-AMC
(0.25–7.5  M; Boston Biochem) in 50 mM Hepes, pH 8.0, and 1 mM
DTT. Liberation of AMC at 23 C was monitored continuously in a micro-
plate reader (excitation/emission wavelengths 380/460 nm; SpectraMax M2;
Molecular Devices). Relative fluorescence units were converted to pmol
AMC using a standard curve of relative fluorescence units versus AMC con-
centration. Kinetic constants (kcat, Km) were calculated from Michaelis-
Menten plots (V0 versus [S]) with nonlinear regression analysis using Graph-
Pad software and the assumption that 100% of purified YopJ was active.
Yersinia infections. Yersinia strains were grown overnight with aeration
in 2x YT medium at 26 C and then diluted 1:50 into 2x YT plus 20 mM
sodium oxalate and 20 mM MgCl2 to be grown for 2 h at 26 C and then
2 h at 37 C. 2   106 RAW264.7 (ATCC TIB71) cells were seeded into six-
well plates at 37 C (5% CO2) for 15–18 h and infected at a multiplicity of
infection of 50:1. Centrifugation at 165 g for 5 min synchronized the infec-
tion. 50  M MG132 was added 1 h before infection.
Online supplemental material. Fig. S1 shows the protease activity of
recombinant SUMO protease 1 or YopJ against ubiquitin-AMC or
SUMO1-AMC. It is available at http://www.jem.org/cgi/content/full/
jem.20051194/DC1.
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Figure 5. Purified YopJ cleaves ubiquitin-AMC but not SUMO-1–
AMC. (A) Coomassie blue staining (left) and anti-His immunoblotting (right) 
of purified YopJ protein. (B) Purified YopJ was incubated with ubiquitin-AMC 
( ) or SUMO1-AMC ( ), and protease activity was determined by the 
release of fluorescent AMC. YopJ mutant C172A had no activity against 
ubiquitin-AMC (*). For WT YopJ, Km   3.0  M, Vmax   7,975 pM s 1, and 
kcat   0.06 s 1. kcat is likely underestimated because the calculation assumed 
that 100% of purified YopJ protein was active and folded correctly.YERSINIA YOPJ ACTS AS A DEUBIQUITINASE | Zhou et al. 1332
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